ReviewFrontiers in immunology2018
T-Cell Metabolism in Hematopoietic Cell Transplantation.
Review in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 34 citations in OpenAlex.
- Dynamic Metabolic Profiling and Diagnostic Biomarkers of Acute Graft-Versus-Host Disease Based on Metabolomics.Biomedical chromatography : BMC · 2026Article
- Targeting the pentose phosphate pathway mitigates graft-versus-host disease by rewiring alloreactive T cell metabolism.JCI insight · 2025Article
- Elevated high-density lipoprotein levels following acute graft-versus-host disease onset: a potential link to T-cell dysfunction and increased relapse risk.Clinical & translational immunology · 2025Article
- Immunometabolic cues recompose and reprogram the microenvironment around implanted biomaterials.Nature biomedical engineering · 2024Article
- Transcriptome analysis of anaerobic glycolysis effects on Jurkat T cell proliferation.Central-European journal of immunology · 2024Article
- Metabolic instruction of the graft-versus-leukemia immunity.Frontiers in immunology · 2024Review
- Chronic GvHD NIH Consensus Project Biology Task Force: evolving path to personalized treatment of chronic GvHD.Blood advances · 2023Article
- Fibroblastic reticular cells mitigate acute GvHD via MHCII-dependent maintenance of regulatory T cells.JCI insight · 2022Article
- Pretransplant Systemic Lipidomic Profiles in Allogeneic Stem Cell Transplant Recipients.Cancers · 2022Article
- Metabolic Reprogramming of Alloreactive T Cells Through TCR/MYC/mTORC1/E2F6 Signaling in aGvHD Patients.Frontiers in immunology · 2022Article
- Immunometabolic Therapeutic Targets of Graft-versus-Host Disease (GvHD).Metabolites · 2021Review
- Neither Donor nor Recipient Mitochondrial Haplotypes Are Associated with Unrelated Donor Transplant Outcomes: A Validation Study from the CIBMTR.Transplantation and cellular therapy · 2021Article
- Regulatory T Cell Therapy of Graft-versus-Host Disease: Advances and Challenges.International journal of molecular sciences · 2021Review
- High Throughput Analysis Reveals Changes in Gut Microbiota and Specific Fecal Metabolomic Signature in Hematopoietic Stem Cell Transplant Patients.Microorganisms · 2021Article
- Thymopoiesis, Alterations in Dendritic Cells and Tregs, and Reduced T Cell Activation in Successful Extracorporeal Photopheresis Treatment of GVHD.Journal of clinical immunology · 2021Observational
- Article
- T-Cell Metabolism in GraftFrontiers in immunology · 2021Review
- Lysosomal Acid Lipase Is Required for Donor T Cells to Induce Graft-versus-Host Disease.Cell reports · 2020Article
- Metabolic Reprogramming-A New Era How to Prevent and Treat Graft Versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Has Begun.Frontiers in pharmacology · 2020Review
- T cell metabolism in graft-versus-host disease.Blood science (Baltimore, Md.) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Metabolism, including catabolism and anabolism, is a basic cellular process necessary for cell survival. T lymphocytes have a distinct metabolism that can determine both fate and function. T-cell activation depends on glycolysis to obtain materials and energy for proliferation and effector function. Importantly, T cells utilize different metabolic processes under different conditions and diseases. Allogeneic hematopoietic cell transplantation (allo-HCT) is a classic immunotherapy for hematological malignancies; however, the development of graft-versus-host disease (GVHD) is a major factor limiting the success of allo-HCT. T cells in the donor graft drive GVHD by mounting a robust immunological attack against recipient normal tissues. Hence, understanding T-cell metabolism after allo-HCT would provide potential metabolic targets for the control of GVHD and primary tumor relapse. The purpose of the current review is to highlight the key metabolic pathways involved in alloantigen-activated T cells and to discuss how manipulating these pathways can serve as potential new therapeutic strategies to induce immune tolerance after allo-transplantation. We will also summarize the recent progress in regulating T-cell metabolism in bone marrow transplantation by targeting novel metabolic regulators or immune checkpoint molecules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.